HUTCHMED (China) Limited (HCM) reported Wednesday that its fiscal 2023 net income attributable to the company was $100.8 million, compared to last year's net loss of $360.8 million.
Earnings were $0.12 per ordinary share / $0.59 per ADS, compared to loss of $0.43 per ordinary share / $2.13 per ADS in 2022.
Revenue grew 97 percent to $838 million from prior year's $426.4 million. The growth was 102 percent at constant exchange rates.
The results were driven by the Takeda partnership, strong commercial progress in China, and growth in third-party distribution sales.
Looking ahead for fiscal 2024, the company sees Oncology/Immunology consolidated revenue to be $300 million to $400 million, driven by 30 percent to 50 percent growth target in oncology marketed product revenue.
In pre-market activity on the NYSE, HUTCHMED shares were gaining around 3.2 percent to trade at $16.50.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.